Random peptide bacteriophage display as a probe for urokinase receptor ligands

Biological Chemistry

Volumn 383, Issue 1, 2002, Pages 149-158

  Fong, Susan ^a   Doyle, Michael V ^a   Goodson, Robert J ^a   Drummond, Robert J ^a   Stratton, Jennifer R ^a   McGuire, Lisa ^a   Doyle, Laura V ^a   Chapman, Harold A ^a   Rosenberg, Steven ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adhesion; Integrins; Invasion; Proteolysis; Vitronectin

Indexed keywords

8 ANILINO 1 NAPHTHALENESULFONIC ACID; ALANINE; LIGAND; PEPTIDE; PEPTIDE LIBRARY; POLYMER; UROKINASE; UROKINASE RECEPTOR; VITRONECTIN; CELL SURFACE RECEPTOR; INTEGRIN; OLIGOPEPTIDE; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS;

ALPHA CHAIN; AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BACTERIOPHAGE; BINDING COMPETITION; BINDING SITE; CELL ADHESION; CELL MIGRATION; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; FLUORESCENCE; GENETIC CODE; MOLECULAR PROBE; MUTAGENESIS; NONHUMAN; PHAGE DISPLAY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR BINDING; SEQUENCE HOMOLOGY; CHEMISTRY; HUMAN; METABOLISM; SOLUBILITY;

ANIMALIA;

ALANINE; AMINO ACID SEQUENCE; BINDING SITES; BINDING, COMPETITIVE; HUMANS; INTEGRINS; LIGANDS; MUTAGENESIS; OLIGOPEPTIDES; PEPTIDE LIBRARY; RECEPTORS, CELL SURFACE; SOLUBILITY; URINARY PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 0036005967     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2002.015     Document Type: Article

References (51)

1. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling
2. The urokinase-type plasminogen activator system in cancer metastasis: A review
3. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system
4. Urokinase receptor interacts with alpha(v) beta5 vitronectin receptor, promoting urokinase-dependent cell migration in breast cancer
5. Protease crosstalk with integrins: The urokinase receptor paradigm
6. Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells
7. Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells
8. Prevention of metastasis by inhibition of the urokinase receptor
9. Urokinase-urokinase receptor interaction: Non-mitogenic signal transduction in human epidermal cells
10. Structural and function analysis of the PAI-1 binding motif in the somatomedin B domain of vitronectin
11. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
12. Random peptide libraries: A source of specific binding molecules
13. The urokinase receptor: Involvement in cell surface proteolysis and cancer invasion
14. Differential binding of urokinase and peptide antagonists to the urokinase receptor: Evidence from characterization of the receptor in four primate species
15. Vitronectin and its receptors
16. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display
17. The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction
18. Critical amino acid residues for ligand binding are clustered in a predicted β-turn of the third N-terminal repeat in the integrin α4 and α5 subunits
19. The urokinase receptor is a major vitronectin-binding protein on endothelial cells
20. Characterization of ligand binding to immobilized biotinylated extracellular domains of three growth factor receptors
21. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
22. Ligand binding regions in the receptor for urokinase-type plasminogen activator: Structural requirements for a multidomain binding region and receptor-receptor interaction
23. Plasminogen activators and matrix metalloproteinases in angiogenesis
24. Nonenzymatic interactions between proteinases and the cell surface: Novel roles in normal and malignant cell physiology
25. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
26. Matrix metalloproteinases: Biologic activity and clinical implications
27. Urokinase receptor and integrin partnership: Coordination of signaling for cell adhesion, migration and growth
28. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assem
29. Ligand interaction between uPA and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor
30. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide-antagonist. Evidence for a composite ligand-binding site and a short interdomain separation
31. Role of vitronectin and its receptors in haemostasis and vascular remodeling
32. Urokinase receptor: A molecular organizer in cellular communication
33. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase
34. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis
35. A method for defining binding sites involved in protein-protein interactions: Analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin
36. Interactions between type 1 plasminogen activator inhibitor, extracellular matrix and vitronectin
37. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin
38. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells
39. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function
40. Yeast expression and phagemid display of the human urokinase plasminogen activator epidermal growth factor-like domain
41. Urokinase receptor antagonists: Discovery and application to in vivo models of tumor growth
42. Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo
43. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy
44. Plasmin and plasminogen activator inhibitor type-1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin
45. Nonproteolytio role for the urokinase receptor in cellular migration in vivo
46. Identification of the urokinase receptor as an adhesion receptor for vitronectin
47. Regulation of integrin function by the urokinase receptor
48. 3
49. Novel purification of vitronectin from human plasma by heparin affinity chromatography
50. Requirement of receptor-bound uPA for integrin alpha-v-beta-5 directed cell migration